北京键凯科技股份有限公司 简式权益变动报告书 上市公司名称：北京键凯科技股份有限公司 股票上市地点：上海证券交易所 股票简称：键凯科技 股票代码：688356 信息披露义务人：吴凯庭 住所及通讯地址：福建省厦门市***** 权益变动性质：减少股份（大宗交易） 签署日期：2025 年 12 月 08 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民 共和国证券法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变 动报告书》及其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》和《公开发行证券的公司信息披露内容 与格式准则第 15 号—权益变动报告书》的规定，本报告书已全面披露信息披露 义务人在北京键凯科技股份有限公司拥有权益的股份变动情况。截至本报告书签 署日，除本报告书披露的持股信息外，上述信息披露义务人没有通过任何其他方 式增加或减少其在北京键凯科技股份有限公司中拥有权益的股份。 四、本次权益变动 ...

Core Viewpoint - The company JianKai Technology (688356.SH) reported a shareholding change involving a reduction in shares held by Wu Kaiting, indicating a slight decrease in his ownership percentage [1] Summary by Sections - **Shareholding Change** - Wu Kaiting reduced his shareholding by 48,200 shares through a block trade on December 8, 2025, decreasing his ownership from 15.08% to 15.00% [1] - After the transaction, Wu Kaiting holds 9.0976 million shares, representing 15.00% of the company's total share capital, which is a significant threshold as it touches the 5% integer multiple [1]

Core Viewpoint - The launch event of SILKROSE, a brand under JianKai Technology, marks a significant milestone in showcasing China's innovative strength in medical beauty materials, particularly with the introduction of PEG cross-linked hyaluronic acid gel [1][7]. Group 1: Event Overview - The event was co-hosted by SILKROSE and Beijing Shouxi Lige, featuring industry experts and leaders discussing the future of the medical beauty industry under the "Healthy China" strategy [3]. - The event emphasized the importance of independent innovation in medical materials technology to promote sustainable development in the medical beauty sector [3]. Group 2: Product Innovation - SILKROSE is positioned as a systematic solution to address pain points in the traditional filling market, aiming to reshape the industry landscape [4]. - The PEG material technology utilized in SILKROSE represents a significant innovation, transitioning the medical beauty industry from "scale growth" to "value innovation" [4]. Group 3: Clinical Application Standards - The new clinical application standards for SILKROSE were presented, highlighting the need for filling materials to provide both dynamic integration and static support [5]. - SILKROSE offers a comprehensive solution for clinical practitioners, including injection techniques and dosage planning, transforming material science innovation into standardized clinical practices [5]. Group 4: Strategic Partnerships - A strategic partnership was established between SILKROSE and Beijing Shouxi Lige, with the latter being awarded the title of "Chief Medical Guidance Expert," enhancing collaboration in the industry [5]. - This partnership exemplifies the synergy between production, academia, research, and application, aiming to set new industry benchmarks [5]. Group 5: Technological Breakthroughs - SILKROSE, as the first domestically developed injectable PEG cross-linked hyaluronic acid gel, underwent nine years of research and received NMPA Class III medical device certification [7]. - The PEG cross-linking technology ensures no residuals remain post-degradation, offering high biocompatibility and a natural filling effect [7]. Group 6: Industry Vision - The event transcended product promotion, fostering discussions on the future of the medical beauty industry and the role of technological innovation in driving industry upgrades [8]. - SILKROSE aims to contribute to a safer, more professional, and healthier development of the medical beauty industry, aligning with the "Healthy China" initiative [8].

Core Points - The company, JianKai Technology, announced the appointment of Mr. Chen Bin as the Secretary of the Board [1] Group 1 - JianKai Technology made an official announcement regarding the hiring of a new board secretary [1]

证券代码：688356 证券简称：键凯科技 公告编号：2025-040 北京键凯科技股份有限公司 关于完成董事会换届选举及 （一）董事选举情况 2025 年 11 月 18 日，公司召开 2025 年第二次临时股东会，通过累积投票制的方式 选举 XUAN ZHAO 先生、韩磊女士、张如军女士、王庆彬先生、LIHONG GUO 女士、 吴伟京女士担任公司第四届董事会非独立董事，选举林雯女士、张杰女士、高巧莉女士 担任公司第四届董事会独立董事。本次股东会选举产生的六名非独立董事和三名独立董 事共同组成公司第四届董事会，任期自股东会审议通过之日起三年。 上述第四届董事会董事简历详见公司于 2025 年 10 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于董事会换届选举的公告》（公告编号:2025-033）。 聘任高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》（以下简称" ...

证券代码：688356 证券简称：键凯科技 公告编号：2025-041 北京键凯科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 1、 公司在任董事9人，出席9人； 2、 董事会秘书陈斌先生出席本次会议，其他高级管理人员列席了本次会议。 | 1、出席会议的股东和代理人人数 | 26 | | --- | --- | | 普通股股东人数 | 26 | | 2、出席会议的股东所持有的表决权数量 | 19,373,852 | | 普通股股东所持有表决权数量 | 19,373,852 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.0214 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.0214 | 注：截至本次股东会股权登记日，公司回购专用证券账户中股份数为 147,914 股，该等回 购股份不享有股东会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规 ...

北京市时代九和律师事务所 关于北京键凯科技股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年十一月 2025 年第二次临时股东会的 法律意见书 致：北京键凯科技股份有限公司 北京市时代九和律师事务所（以下简称"本所"）接受北京键凯科技股份有 限公司（以下简称"公司"）委托，指派陆群威律师和谢淮桉律师列席了公司 2025 年第二次临时股东会（以下简称"本次股东会"），就本次股东会的相关事项进行 见证，并出具法律意见书。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）等相关法律法规、规范性文件以及《北京键凯科技股份 有限公司章程》（以下简称"《公司章程》"）的规定出具。 为出具本法律意见书，本所律师审查了公司提供的与本次股东会有关的文件、 资料及相关材料。本所律师出具本法律意见书基于公司向本所律师提供的一切原 始文件、副本材料均真实、准确、完整、有效，不存在虚假记载、误导性陈述或 者重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材料均 与正本或原始材料 ...

Core Viewpoint - The announcement details the results of a share transfer by XUAN ZHAO, the controlling shareholder of Beijing JianKai Technology Co., Ltd, involving the transfer of 1,819,521 shares at a price of 76.18 yuan per share, which will reduce his shareholding from 24.56% to 21.56% [2][3][6]. Group 1: Transfer Details - The share transfer price is set at 76.18 yuan per share, with a total of 1,819,521 shares being transferred [2]. - The transfer will not result in a change of control for the company, as XUAN ZHAO and his concerted parties will still hold a significant portion of shares [3][7]. - The transfer process involved 194 institutional investors receiving the subscription invitation, with 27 valid bids submitted during the specified time [6][7]. Group 2: Shareholder Information - XUAN ZHAO is identified as the controlling shareholder, actual controller, chairman, and general manager of the company, holding more than 5% of the shares prior to the transfer [4]. - XUAN ZHAO and LIHONG GUO are recognized as concerted parties due to their marital relationship, although LIHONG GUO did not participate in this transfer [4]. Group 3: Compliance and Regulation - The share transfer process adhered to principles of fairness and compliance with relevant securities market regulations, including the Company Law and Securities Law of the People's Republic of China [8].

Core Viewpoint - On November 17, 19 A-share listed companies disclosed shareholding reductions, while Huangtai Liquor Industry announced a plan for share repurchase ranging from 70 million to 140 million yuan [1][2]. Group 1: Shareholding Increases - Huangtai Liquor Industry's controlling shareholder plans to increase its stake in the company by 70 million to 140 million yuan [2]. Group 2: Shareholding Reductions - Fubon Technology's specific shareholder, Zhenghong Development, intends to reduce its stake by no more than 0.59% [2]. - Huijie Co., Ltd.'s shareholder Lin Shengzhi plans to reduce his stake by no more than 2% [2]. - Chengdu Huamei's shareholders plan to reduce their stakes [2]. - Dexin Technology's shareholder Xinjiang Guotou plans to reduce by no more than 1% [2]. - Gokai Technology's major shareholder plans to reduce by no more than 0.7% [2]. - Fulin Precision's second-largest shareholder, An Zhifu, plans to reduce by no more than 1% [2]. - Zhouming Technology's controlling shareholder Lin Zhaofeng plans to reduce by no more than 1.99% [2]. - Keheng Co., Ltd.'s shareholder Wang Guojiang plans to reduce by no more than 2% [2]. - Yijiahe's shareholder Zhejiang Junhong plans to reduce by no more than 2% [2]. - Tianqi Co., Ltd.'s director Shen Baowei plans to reduce by no more than 0.0631% [2]. - Jiankai Technology's controlling shareholder is transferring 1.8195 million shares [2]. - Huizhiwei's shareholder GZPA plans to reduce by no more than 2.25% [2]. - Xingli Food's shareholder Shanghai Houxu plans to reduce by no more than 3% [2]. - Tiejie Technology's largest shareholder Alibaba Network reduced its stake by 4.2392 million shares from November 6 to November 17 [2]. - Shengke Communication's second-largest shareholder, the National Fund, reduced its stake by 10.1891 million shares from August 25 to November 17 [2]. - Yayi International's shareholder Zhongnong Group plans to reduce by no more than 1% [2]. - Yatai Co., Ltd.'s controlling shareholder Yatai Group plans to reduce by no more than 1% [2]. - Guangge Technology's shareholders, Jishi Chuangtou and Fangguang No. 2, plan to reduce their stakes by no more than 3.99% [2]. - Kaichuang International's Xiaojian Technology and its concerted actions reduced their stakes by 2.9321 million shares from November 7 to November 17 [2].

证券代码：688356 证券简称：键凯科技 公告编号：2025-039 北京键凯科技股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%整数倍的提示性公告 XUAN ZHAO（以下简称"转让方"）保证向北京键凯科技股份有限公司（以下简 称"键凯科技"或"公司"）提供的信息内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 一、 转让方情况 (一)转让方基本情况 截至 2025 年 11 月 11 日，转让方所持首发前股份的数量、占键凯科技总股本 比例情况如下： | | | 本次询价转让的价格为76.18元/股，转让的股票数量为1,819,521股。 公司控股股东、实际控制人、董事长、总经理 XUAN ZHAO参与本次询价转 让。 本次转让不会导致公司控股股东、实际控制人发生变化。 本次权益变动后，XUAN ZHAO 及其一致行动人合计持有上市公司股份比例 将从 24.56%减少至 21.56%，持有公司权益比例变动触及 1%的整数倍。 | | | 本次询价转 ...